<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Summers, Jaye</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Repovic, Pavle</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Disease Activity in Year 1 Predicts Long-term Outcomes in Patients Taking Fingolimod</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-05-20 11:31:42</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-17</style></pages><abstract><style  face="normal" font="default" size="100%">In patients with relapsing multiple sclerosis who participated in the TRANSFORMS trial, magnetic resonance imaging activity and relapses in the first year predicted clinical outcomes over 3 years of the extension trial. Switching from interferon beta-1a to fingolimod at 12 months reduced the proportion of patients with focal magnetic resonance imaging activity and relapse by 70%.</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>